Literature DB >> 19180987

Effects of lipopolysaccharide endotoxin on the insulin-like growth factor I system in rats with cirrhosis.

Karen Louise Thomsen1, Susanne Schouw Nielsen, Henning Grønbiek, Allan Flyvbjerg, Hendrik Vilstrup.   

Abstract

BACKGROUND: Patients with liver cirrhosis have disturbances in the insulin-like growth factor I (IGF-I) system that favour insulin resistance and catabolism. High morbidity and mortality of such patients from infections may be related to further aggravation of this problem but human data are controversial. Here, the effect of lipopolysaccharide (LPS) endotoxin on the IGF system was studied in rats with cirrhosis.
MATERIALS AND METHODS: One month after induction of cirrhosis by bile duct ligation, LPS was administered (0.5 mg/kg) and the IGF system assessed 24 h later. Sham-operated animals acted as controls. Circulating and liver mRNA of IGF-I and its binding proteins (IGFBPs) were measured.
RESULTS: LPS reduced IGF-I and IGFBP-3 by 20% in the cirrhosis group. LPS induced insulin resistance (HOMA) in both groups.
CONCLUSION: Our results show that LPS administered to cirrhotic rats induced changes in the IGF system that facilitate catabolism. This may be of importance for the accelerated tissue loss during infection and the acute phase response in liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19180987

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  2 in total

1.  IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats.

Authors:  Tian-Yu Zhao; Li-Ping Su; Chun-Ye Ma; Xiao-Han Zhai; Zhi-Jun Duan; Ying Zhu; Gang Zhao; Chun-Yan Li; Li-Xia Wang; Dong Yang
Journal:  BMC Gastroenterol       Date:  2015-07-08       Impact factor: 3.067

2.  Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis.

Authors:  Koji Murata; Kosuke Kaji; Norihisa Nishimura; Masahide Enomoto; Yuki Fujimoto; Soichi Takeda; Yuki Tsuji; Yukihisa Fujinaga; Hiroaki Takaya; Hideto Kawaratani; Tadashi Namisaki; Takemi Akahane; Hitoshi Yoshiji
Journal:  Int J Mol Med       Date:  2022-06-10       Impact factor: 5.314

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.